- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03127878
Effects of Upper-limb Training Addition to a Conventional ET Program on PA Level and ADL Performance.
Effects of Upper-limb Endurance Exercise Training Addition to a Conventional High-intensity Exercise Training Program on Physical Activity Level and Activities of Daily Living Performance in Patients With COPD
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Patients with chronic obstructive pulmonary disease (COPD; n=64) will be recruited by convenience and, thereafter, included in this randomized controlled clinical trial. The execution of all the procedures involved in this study will be performed at the Laboratory of Research in Respiratory Physiotherapy (LFIP), located at the University Hospital of the State University of Londrina, Brazil. Prior to starting the exercise training program patients will be evaluated regarding: 1) physical activity in daily life (PADL) by the MoveMonitor (McRoberts, The Netherlands) and by the ActGraph (ActGraph, USA) for seven consecutive days during awake time; 2) lung function by plethysmography; 3) maximum ins- and expiratory pressures (MIP and MEP, respectively) by manovacuometry; 4) body composition by bioelectrical impedance; 5) Performance in activities of daily living (ADL) by the Londrina ADL protocol (LAP), a protocol recently developed at our laboratory, composed by five common activities usually performed by the patients in real life situations; 6) Maximum exercise capacity by the symptom limited maximum test on lower- (increase of 10 watts/minute at a cadence of 50-60 rotations per minute [rpm]) and upper-limbs (5 watts/min at a cadence of 50-60 rpm) performed on cycle ergometer; 7) submaximal exercise capacity (endurance time) for the lower- and upper- limbs at 80% peak work of the respective maximum exercise capacity; 8) functional exercise capacity by the six-minute walk test and the six-minute pegboard and ring test; 9) peripheral muscle strength by the one-repetition maximum test (quantified in kg) of the knee extensors, hip abductors, elbow flexors and extensors, shoulder adductors, and dorsal muscles; and by isometric dynamometry (quantified by kgf) of the quadriceps; 10) Health-related quality of life by the Chronic Respiratory Questionnaire; 11) Health status by the COPD assessment test; 12) functional status by the London Chest Activity of Daily Living scale; 13) symptoms of anxiety and depression by the Hospital Anxiety and Depression scale; 14) and dyspnea sensation in daily life by the Medical Research Council scale. Internationally applied protocols will be followed for all the above-mentioned procedures, and local reference values will be used when appropriated. After the evaluations, patients will be randomly allocated for the traditional exercise-training program (TET) or to TET plus additional upper-limb endurance exercise-training program group (AULET).
After randomization, patients allocated to the TET group will perform lower-limb endurance exercise training on treadmill and on cycle ergometer. For the treadmill, patients will start exercising at 70% of the six-minute walk test average speed and, progressively, the intensity will be increased up to 110% of the six-minute walk test average speed until the last week of the program. For the cycle ergometer, the intensity will start at 60% of the maximum exercise capacity increasing up to 100% until the last week of the program.
For the exercise performed both on treadmill and on cycle, patients will start exercising for 10 minutes, aiming to achieve 20 minutes at the last week. In addition to the pre-schedule intensity-progression, the Borg scale (0 - 10) also will be used as auxiliary tool for guiding the exercise-intensity progression throughout the program. Additionally, patients will perform strengthening exercises for the knee-extensors, hip abductors and adductors, elbow flexors and extensors, shoulder adductors and dorsal muscles. For the strengthening exercises the intensity will start at 60% of the one-repetition maximum test increasing up to 100%. For all muscle groups, strengthening exercises will start with three series of ten repetitions, and progression is intended to achieve three series of 15 repetition by the last week. In addition to the exercises that the TET will be submitted, patients in the AULET will perform additional upper-limb endurance exercises on arm-cycle ergometer, starting at 60% of the maximum exercise capacity, for ten minutes, progressing until 95% of the maximum exercise capacity for 20 minutes in the last week. Borg scale will be used as in the TET to guide exercise-training intensity progression for the upper-limb cycling. In both groups, vital sings (i.e., heart rate, arterial pressure and peripheral oxygen saturation [SPO2]) will be continuously monitored throughout exercise-training sessions. Noteworthy, for those patients developing exercise desaturation (i.e., SPO2 bellow 90% or a drop higher than 4%) oxygen will be offered at a dosage enough to increase peripheral saturation above the desaturation nadir. Patients composing both groups will also receive educational sessions about topics related to disease burden, treatment and self-management.
Study Type
Enrollment (Anticipated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Fabio Pitta, PhD
- Phone Number: +554333712477
- Email: fabiopitta@uol.com.br
Study Locations
-
-
Parana
-
Londrina, Parana, Brazil, 86038350
- Recruiting
- State University of Londrina
-
Contact:
- Fabio Pitta, PhD
- Phone Number: +554333712477
- Email: fabiopitta@uol.com.br
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Diagnose of chronic obstructive pulmonary disease according to the Global Initiative for chronic obstructive lung disease
- Absence of exacerbation in the previous month (clinical stability)
- Absence of severe or non-stable cardiac disease
- Absence of conditions able to impair the execution of the tests or the proposed treatment
- Do not be part of any exercise training program in the previous year
Exclusion Criteria:
- Severe exacerbation of the disease needing long-term hospitalisation
- Development of others conditions or diseases able to interfere in the proposed treatment or its results
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
ACTIVE_COMPARATOR: Active-control
High-intensity endurance exercise of lower-limb with strengthening exercise of upper- and lower-limb
|
|
EXPERIMENTAL: Upper-limb additional training
High-intensity endurance exercise of upper- and lower-limb with strengthening exercise of upper- and lower-limb
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Changes in active time
Time Frame: at the entrance on the study and after at 3 months.
|
Changes in time spend (in minutes) in daily life in activities above 3 Metabolic Equivalent of Task (METs)
|
at the entrance on the study and after at 3 months.
|
Changes in sedentary time
Time Frame: at the entrance on the study and after at 3 months.
|
Changes in time (in minutes) spend in daily life in activities bellow 1.5 METs
|
at the entrance on the study and after at 3 months.
|
Changes in performance in activities of daily living
Time Frame: at the entrance on the study and after at 3 months.
|
Changes in time (in seconds) to perform a protocol that is composed by 5 activities of daily living (The Londrina ADL protocol [LAP])
|
at the entrance on the study and after at 3 months.
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Changes in lung function
Time Frame: at the entrance on the study and after at 3 months.
|
Changes in lung flows (l/min) acquired by plethysmography
|
at the entrance on the study and after at 3 months.
|
Changes in lung function
Time Frame: at the entrance on the study and after at 3 months.
|
Changes in lung volumes (l) acquired plethysmography
|
at the entrance on the study and after at 3 months.
|
Changes in lung function
Time Frame: at the entrance on the study and after at 3 months.
|
Changes in lung capacities (l) acquired plethysmography
|
at the entrance on the study and after at 3 months.
|
Changes in respiratory muscle strength
Time Frame: at the entrance on the study and after at 3 months.
|
Change in maximum expiratory pressures (cmH2O) acquired by manovacuometry
|
at the entrance on the study and after at 3 months.
|
Changes in respiratory muscle strength
Time Frame: at the entrance on the study and after at 3 months.
|
Change in maximum inspiratory pressures (cmH2O) acquired by manovacuometry
|
at the entrance on the study and after at 3 months.
|
Changes in body composition
Time Frame: at the entrance on the study and after at 3 months.
|
Changes in fat-free mass index (kg/m2) acquired by bioelectrical impedance
|
at the entrance on the study and after at 3 months.
|
Changes in lower-limb maximum exercise capacity
Time Frame: at the entrance on the study and after at 3 months.
|
Changes in maximum exercise capacity (watts) of the lower-limbs by a symptom limited maximum test on lower-limb ergometer.
|
at the entrance on the study and after at 3 months.
|
Changes in upper-limb maximum exercise capacity
Time Frame: at the entrance on the study and after at 3 months.
|
Changes in maximum exercise capacity (watts) of the upper-limbs by a symptom limited maximum test on upper-limb ergometer.
|
at the entrance on the study and after at 3 months.
|
Changes in lower-limb submaximal exercise capacity
Time Frame: at the entrance on the study and after at 3 months.
|
Changes in endurance time (seconds) during a constant load test for lower-limb at 80% of maximum exercise capacity on lower-limb ergometer.
|
at the entrance on the study and after at 3 months.
|
Changes in upper-limb submaximal exercise capacity
Time Frame: at the entrance on the study and after at 3 months.
|
Changes in endurance time (seconds) during a constant load test for upper-limb at 80% of maximum exercise capacity on upper-limb ergometer.
|
at the entrance on the study and after at 3 months.
|
Changes in lower-limb functional exercise capacity
Time Frame: at the entrance on the study and after at 3 months.
|
Changes in the distance walked (meters) by the patients during the Six-minute Walk Test
|
at the entrance on the study and after at 3 months.
|
Changes in upper-limb Functional Exercise Capacity
Time Frame: at the entrance on the study and after at 3 months.
|
Changes in the number of rings moved by the patients during the Six-minute pegboard and Ring Test
|
at the entrance on the study and after at 3 months.
|
Changes in peripheral muscle strength
Time Frame: at the entrance on the study and after at 3 months.
|
The maximum load (kg) lifted up by the patients during the one-repetition maximum test of upper- and lower-limbs
|
at the entrance on the study and after at 3 months.
|
Changes in isometric peripheral muscle strength
Time Frame: at the entrance on the study and after at 3 months.
|
Changes in maximum isometric load (kgf) performed by the patients during the dynamometry of the quadriceps muscle
|
at the entrance on the study and after at 3 months.
|
Changes in health-related quality of life
Time Frame: at the entrance on the study and after at 3 months.
|
Changes in healthy-related quality of life score by the Chronic Respiratory Questionnaire
|
at the entrance on the study and after at 3 months.
|
Health Status
Time Frame: at the entrance on the study and after at 3 months.
|
Quantification of the healthy status by the COPD Assessment Test score
|
at the entrance on the study and after at 3 months.
|
Functional Status
Time Frame: at the entrance on the study and after at 3 months.
|
Quantification of the functional status by the London Chest Activity of Daily Life scale score
|
at the entrance on the study and after at 3 months.
|
Change in anxiety and depression
Time Frame: at the entrance on the study and after at 3 months.
|
Changes in anxiety and depression symptoms by the Hospital Anxiety and Depression scale score
|
at the entrance on the study and after at 3 months.
|
Changes in dyspnea sensation in daily life
Time Frame: at the entrance on the study and after at 3 months.
|
Changes in the impact of dyspnea in the performance of daily living activities by the Medical Research Council scale score
|
at the entrance on the study and after at 3 months.
|
Collaborators and Investigators
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ANTICIPATED)
Study Completion (ANTICIPATED)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ACTUAL)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 070566/2016
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Pulmonary Disease, Chronic Obstructive
-
Spire, Inc.ResMedCompletedSevere Chronic Obstructive Pulmonary Disease | Moderate Chronic Obstructive Pulmonary DiseaseUnited States
-
Karaganda Medical UniversityCompletedChronic Obstructive Pulmonary Disease | Chronic Obstructive Pulmonary Disease Moderate | Chronic Obstructive Pulmonary Disease SevereKazakhstan
-
Randall DebattistaUniversity of Malta, Faculty of Health SciencesNot yet recruitingChronic Obstructive Pulmonary Disease Moderate | Acute Exacerbation of COPD | Chronic Obstructive Pulmonary Disease Severe
-
Cukurova UniversityCompletedAnesthesia | Chronic Obstructive Pulmonary Disease Moderate | Lungcancer | Chronic Obstructive Pulmonary Disease Severe | Chronic Obstructive Pulmonary Disease MildTurkey
-
National Taipei University of Nursing and Health...TerminatedChronic Pulmonary Disease | Chronic Obstructive Pulmonary Disease Exacerbation | Chronic Obstructive Pulmonary Disease With ExacerbationTaiwan
-
Taipei Medical UniversityUnknownChronic Obstructive Pulmonary Disease Severe | Chronic Obstructive Pulmonary Disease End StageTaiwan
-
Mylan Inc.Theravance BiopharmaCompletedChronic Obstructive Pulmonary Disease (COPD)United States
-
University Hospital, GhentGlaxoSmithKline; University GhentCompletedChronic Obstructive Pulmonary Disease (COPD)Belgium
-
Optimum Patient CareRespiratory Effectiveness Group; Boehringer Ingelheim Pharmaceutical Company... and other collaboratorsUnknownChronic Obstructive Pulmonary Disease (13645005)United States
-
Poitiers University HospitalCompletedBroncho Chronic Obstructive Pulmonary DiseaseFrance
Clinical Trials on Exercise
-
University of Kansas Medical CenterRecruiting
-
National Institute of Neurological Disorders and...TerminatedTraumatic Brain InjuryUnited States
-
University of Texas, El PasoRecruitingKnee Osteoarthritis | Knee Pain Chronic | Central Pain SyndromeUnited States
-
Toronto Rehabilitation InstituteCompletedAcute Myeloid LeukemiaCanada
-
Sahmyook UniversityRecruitingChronic Nonspecific Neck PainKorea, Republic of
-
University of AlbertaWomen and Children's Health Research Institute, CanadaRecruitingType 1 Diabetes | Post-menopauseCanada
-
Uskudar UniversityCompleted
-
Yuksek Ihtisas UniversityCompletedDementia | Frailty | Cognitive Function | Reaction Time | Aerobic Exercise | Balance ExerciseTurkey
-
National Taiwan Normal UniversityCompletedAging | Cognitive DeclineTaiwan
-
Wayne State UniversityUnknown